Kineta (STU:J75) Accounts Payable : €5.64 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Kineta Accounts Payable?

Kineta's Accounts Payable for the quarter that ended in Mar. 2024 was €5.64 Mil.

Kineta's quarterly Accounts Payable declined from Sep. 2023 (€4.06 Mil) to Dec. 2023 (€3.39 Mil) but then increased from Dec. 2023 (€3.39 Mil) to Mar. 2024 (€5.64 Mil).

Kineta's annual Accounts Payable increased from Dec. 2021 (€0.65 Mil) to Dec. 2022 (€6.26 Mil) but then declined from Dec. 2022 (€6.26 Mil) to Dec. 2023 (€3.39 Mil).

Kineta Accounts Payable Historical Data

The historical data trend for Kineta's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Accounts Payable Chart

Kineta Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Payable

0.95

0.65

6.26

3.39

Kineta Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial							9.19	5.64	4.06	3.39	5.64

Kineta Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Kineta Accounts Payable Related Terms

Thank you for viewing the detailed overview of Kineta's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Kineta (STU:J75) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (STU:J75) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

KA:USA

Address

219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109

Website

https://www.kinetabio.com

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Kineta (STU:J75) Headlines

No Headlines